爭光股份(301092.SZ):擬投建爭光總部經濟及功能性高分子新材料研究院項目
格隆匯8月2日丨爭光股份(301092.SZ)公佈,為持續推進公司總體發展戰略,進一步提升公司的核心競爭力,實現公司的健康、可持續發展,公司擬與杭州餘杭經濟技術開發區管理委員會(“甲方”)簽署《招商協議書》,公司擬計劃以自有資金投資建設“爭光總部經濟及功能性高分子新材料研究院項目”(“爭光總部項目”),公司作為爭光總部項目實施主體。爭光總部項目將用於建設爭光總部及功能性高分子新材料研究院。爭光總部項目計劃總投資約1.47億元(含)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.